Antibody-drug conjugates (ADCs) represent a transformative class of biopharmaceuticals designed to selectively deliver cytotoxic agents to cancer cells. By combining the precision of monoclonal antibodies with the potency of chemotherapy, ADCs minimize systemic toxicity while maximizing therapeutic impact.
